{
    "2019-06-28": [
        [
            {
                "time": "2018-05-14",
                "original_text": "Boston Scientific May Be Too Rich for Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Boston Scientific",
                        "Johnson & Johnson",
                        "acquisition"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-06-17",
                "original_text": "J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma",
                "features": {
                    "keywords": [
                        "Darzalex",
                        "FDA approval",
                        "multiple myeloma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-22",
                "original_text": "Highly Rated Biotech Downgraded After Breaking Out And Running 39%",
                "features": {
                    "keywords": [
                        "downgrade",
                        "price increase",
                        "biotech"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-10",
                "original_text": "Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger",
                "features": {
                    "keywords": [
                        "ABBV",
                        "AGN",
                        "BMY",
                        "CELG",
                        "merger"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-11-05",
                "original_text": "Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow Further?",
                "features": {
                    "keywords": [
                        "Roche",
                        "revenue growth",
                        "therapeutic area"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-12",
                "original_text": "Martin Gilbert branches out",
                "features": {
                    "keywords": [
                        "Martin Gilbert",
                        "business expansion"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}